Goldman Sachs Reinstates Neutral on BioMarin Pharmaceutical, Announces $69 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 58.6%

Neg 0% Neu 58.6% Pos 0%

Goldman Sachs analyst Salveen Richter reinstates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and announces $69 price target.